vs
Side-by-side financial comparison of LivaNova PLC (LIVN) and TransMedics Group, Inc. (TMDX). Click either name above to swap in a different company.
LivaNova PLC is the larger business by last-quarter revenue ($360.9M vs $160.8M, roughly 2.2× TransMedics Group, Inc.). TransMedics Group, Inc. runs the higher net margin — 65.6% vs 8.6%, a 57.0% gap on every dollar of revenue. On growth, TransMedics Group, Inc. posted the faster year-over-year revenue change (32.2% vs 12.1%). LivaNova PLC produced more free cash flow last quarter ($50.2M vs $19.0M). Over the past eight quarters, TransMedics Group, Inc.'s revenue compounded faster (28.8% CAGR vs 10.6%).
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
TransMedics Group, Inc. develops and commercializes innovative medical technologies for organ transplantation. Its flagship Organ Care System keeps donor organs viable during transport, improving transplant outcomes for heart, lung, liver and kidney recipients. It serves transplant centers and organ procurement organizations across North America, Europe and Asia-Pacific.
LIVN vs TMDX — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $360.9M | $160.8M |
| Net Profit | $30.9M | $105.4M |
| Gross Margin | 65.2% | 58.1% |
| Operating Margin | 11.8% | 13.2% |
| Net Margin | 8.6% | 65.6% |
| Revenue YoY | 12.1% | 32.2% |
| Net Profit YoY | -44.7% | 1436.9% |
| EPS (diluted) | $0.57 | $2.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $360.9M | $160.8M | ||
| Q3 25 | $357.8M | $143.8M | ||
| Q2 25 | $352.5M | $157.4M | ||
| Q1 25 | $316.9M | $143.5M | ||
| Q4 24 | $321.8M | $121.6M | ||
| Q3 24 | $318.1M | $108.8M | ||
| Q2 24 | $318.6M | $114.3M | ||
| Q1 24 | $294.9M | $96.8M |
| Q4 25 | $30.9M | $105.4M | ||
| Q3 25 | $26.8M | $24.3M | ||
| Q2 25 | $27.2M | $34.9M | ||
| Q1 25 | $-327.3M | $25.7M | ||
| Q4 24 | $55.9M | $6.9M | ||
| Q3 24 | $33.0M | $4.2M | ||
| Q2 24 | $16.3M | $12.2M | ||
| Q1 24 | $-41.9M | $12.2M |
| Q4 25 | 65.2% | 58.1% | ||
| Q3 25 | 68.4% | 58.8% | ||
| Q2 25 | 67.8% | 61.4% | ||
| Q1 25 | 69.7% | 61.5% | ||
| Q4 24 | 68.2% | 59.2% | ||
| Q3 24 | 70.8% | 55.9% | ||
| Q2 24 | 68.7% | 60.6% | ||
| Q1 24 | 70.3% | 61.9% |
| Q4 25 | 11.8% | 13.2% | ||
| Q3 25 | 15.1% | 16.2% | ||
| Q2 25 | 15.4% | 23.2% | ||
| Q1 25 | 15.3% | 19.1% | ||
| Q4 24 | 11.5% | 7.1% | ||
| Q3 24 | 11.2% | 3.6% | ||
| Q2 24 | 12.6% | 10.9% | ||
| Q1 24 | 5.5% | 12.8% |
| Q4 25 | 8.6% | 65.6% | ||
| Q3 25 | 7.5% | 16.9% | ||
| Q2 25 | 7.7% | 22.2% | ||
| Q1 25 | -103.3% | 17.9% | ||
| Q4 24 | 17.4% | 5.6% | ||
| Q3 24 | 10.4% | 3.9% | ||
| Q2 24 | 5.1% | 10.7% | ||
| Q1 24 | -14.2% | 12.6% |
| Q4 25 | $0.57 | $2.59 | ||
| Q3 25 | $0.49 | $0.66 | ||
| Q2 25 | $0.50 | $0.92 | ||
| Q1 25 | $-6.01 | $0.70 | ||
| Q4 24 | $1.04 | $0.19 | ||
| Q3 24 | $0.60 | $0.12 | ||
| Q2 24 | $0.30 | $0.35 | ||
| Q1 24 | $-0.78 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $635.6M | — |
| Total DebtLower is stronger | $376.1M | — |
| Stockholders' EquityBook value | $1.2B | $473.1M |
| Total Assets | $2.6B | $1.1B |
| Debt / EquityLower = less leverage | 0.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $635.6M | — | ||
| Q3 25 | $646.1M | — | ||
| Q2 25 | $593.6M | — | ||
| Q1 25 | $738.4M | — | ||
| Q4 24 | $428.9M | — | ||
| Q3 24 | $346.4M | $330.1M | ||
| Q2 24 | $329.2M | $362.8M | ||
| Q1 24 | $309.2M | $350.2M |
| Q4 25 | $376.1M | — | ||
| Q3 25 | $434.5M | — | ||
| Q2 25 | $430.6M | — | ||
| Q1 25 | $628.2M | — | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $625.5M | — | ||
| Q2 24 | $624.5M | — | ||
| Q1 24 | $623.8M | — |
| Q4 25 | $1.2B | $473.1M | ||
| Q3 25 | $1.2B | $355.2M | ||
| Q2 25 | $1.1B | $318.1M | ||
| Q1 25 | $1.0B | $266.3M | ||
| Q4 24 | $1.3B | $228.6M | ||
| Q3 24 | $1.3B | $209.9M | ||
| Q2 24 | $1.2B | $189.9M | ||
| Q1 24 | $1.2B | $159.5M |
| Q4 25 | $2.6B | $1.1B | ||
| Q3 25 | $2.6B | $946.0M | ||
| Q2 25 | $2.5B | $890.5M | ||
| Q1 25 | $2.6B | $837.5M | ||
| Q4 24 | $2.5B | $804.1M | ||
| Q3 24 | $2.5B | $785.6M | ||
| Q2 24 | $2.5B | $758.6M | ||
| Q1 24 | $2.5B | $723.8M |
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.51× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.4M | $34.5M |
| Free Cash FlowOCF − Capex | $50.2M | $19.0M |
| FCF MarginFCF / Revenue | 13.9% | 11.8% |
| Capex IntensityCapex / Revenue | 8.9% | 9.7% |
| Cash ConversionOCF / Net Profit | 2.67× | 0.33× |
| TTM Free Cash FlowTrailing 4 quarters | $173.3M | $133.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.4M | $34.5M | ||
| Q3 25 | $85.1M | $69.6M | ||
| Q2 25 | $62.9M | $91.6M | ||
| Q1 25 | $24.0M | $-2.9M | ||
| Q4 24 | $78.7M | $19.7M | ||
| Q3 24 | $51.0M | $6.9M | ||
| Q2 24 | $43.4M | $25.7M | ||
| Q1 24 | $10.0M | $-3.4M |
| Q4 25 | $50.2M | $19.0M | ||
| Q3 25 | $62.2M | $61.9M | ||
| Q2 25 | $47.8M | $82.5M | ||
| Q1 25 | $13.2M | $-29.9M | ||
| Q4 24 | $68.3M | $6.1M | ||
| Q3 24 | $32.8M | $-41.3M | ||
| Q2 24 | $31.2M | $2.0M | ||
| Q1 24 | $3.6M | $-47.6M |
| Q4 25 | 13.9% | 11.8% | ||
| Q3 25 | 17.4% | 43.1% | ||
| Q2 25 | 13.6% | 52.4% | ||
| Q1 25 | 4.2% | -20.8% | ||
| Q4 24 | 21.2% | 5.0% | ||
| Q3 24 | 10.3% | -38.0% | ||
| Q2 24 | 9.8% | 1.7% | ||
| Q1 24 | 1.2% | -49.2% |
| Q4 25 | 8.9% | 9.7% | ||
| Q3 25 | 6.4% | 5.3% | ||
| Q2 25 | 4.3% | 5.8% | ||
| Q1 25 | 3.4% | 18.8% | ||
| Q4 24 | 3.2% | 11.2% | ||
| Q3 24 | 5.7% | 44.3% | ||
| Q2 24 | 3.8% | 20.8% | ||
| Q1 24 | 2.2% | 45.6% |
| Q4 25 | 2.67× | 0.33× | ||
| Q3 25 | 3.18× | 2.86× | ||
| Q2 25 | 2.32× | 2.62× | ||
| Q1 25 | — | -0.11× | ||
| Q4 24 | 1.41× | 2.87× | ||
| Q3 24 | 1.55× | 1.63× | ||
| Q2 24 | 2.65× | 2.11× | ||
| Q1 24 | — | -0.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
TMDX
| Liver Product | $127.0M | 79% |
| Heart Product | $26.0M | 16% |
| Other | $5.9M | 4% |
| Lung Product | $1.9M | 1% |
